Regenerative Technology Treats Acute and Chronic Wounds
|
By HospiMedica International staff writers Posted on 11 Feb 2020 |
|
Image: A sheet of the StimLabs Corplex allograft (Photo courtesy of Stimlabs)
An allograft made of dehydrated human umbilical cord tissue serves as a barrier membrane over acute and chronic wounds.
The StimLabs (Roswell, GA, USA) Corplex allograft is intended to facilitate the repair, reconstruction, replacement, or supplementation of injured tissue, by providing a robust matrix and protective barrier during wound remodeling. It is supplied in a sheet format for use in patients with chronic or acute wounds, especially tunneling wounds where a thicker sheet is warranted. Corplex complements StimLabs' portfolio of products, which includes Ascent, made of dehydrated cells and cellular components retained from amniotic fluid in an injectable format; and Revita, an intact human placental membrane allograft that preserves all layers of the native tissue in a shelf-stable format.
Corplex preserves structural umbilical cord tissue constituents using StimLabs’ patent-pending Clearify process, which retains key extracellular matrix (ECM) components, such as collagens, proteoglycans, and glycosaminoglycans, from both the epithelial layer and the Wharton's Jelly section of the umbilical cord tissue, while effectively cleaning and terminally sterilizing the graft. Corplex is shelf-stable for up to five years and is offered in various sheet sizes (15 mm, 2x2 cm, 2x3 cm, and 3x5 cm).
“Since StimLabs' inception, it's been our promise to deliver more targeted approaches to influence healing through accessibility, ease of use, and effectiveness, to ultimately improve patient outcomes,” said Sarah Griffiths, PhD, VP of Research and Development at StimLabs. “We've worked diligently to ensure these patent-pending processes and products are another step towards that aspiration. We're excited to continue pushing our product portfolio boundaries to more effectively meet the needs of both patients and providers.”
The umbilical cord (UC) is an essential part of the placenta, forming within the first weeks of gestation by the enclosure of blood vessels into a bulk of mucous connective tissue, named Wharton's jelly, and lined by the umbilical epithelium. The cells populating each component of the cord--Wharton's jelly, the lining epithelium, the sub-amnion layer, the perivascular region, and the blood vessels--are a reservoir of progenitor populations which are collectively grouped as mesenchymal stem cells (MSCs), which can differentiate towards mature cell types belonging to all the three germ layers.
Related Links:
StimLabs
The StimLabs (Roswell, GA, USA) Corplex allograft is intended to facilitate the repair, reconstruction, replacement, or supplementation of injured tissue, by providing a robust matrix and protective barrier during wound remodeling. It is supplied in a sheet format for use in patients with chronic or acute wounds, especially tunneling wounds where a thicker sheet is warranted. Corplex complements StimLabs' portfolio of products, which includes Ascent, made of dehydrated cells and cellular components retained from amniotic fluid in an injectable format; and Revita, an intact human placental membrane allograft that preserves all layers of the native tissue in a shelf-stable format.
Corplex preserves structural umbilical cord tissue constituents using StimLabs’ patent-pending Clearify process, which retains key extracellular matrix (ECM) components, such as collagens, proteoglycans, and glycosaminoglycans, from both the epithelial layer and the Wharton's Jelly section of the umbilical cord tissue, while effectively cleaning and terminally sterilizing the graft. Corplex is shelf-stable for up to five years and is offered in various sheet sizes (15 mm, 2x2 cm, 2x3 cm, and 3x5 cm).
“Since StimLabs' inception, it's been our promise to deliver more targeted approaches to influence healing through accessibility, ease of use, and effectiveness, to ultimately improve patient outcomes,” said Sarah Griffiths, PhD, VP of Research and Development at StimLabs. “We've worked diligently to ensure these patent-pending processes and products are another step towards that aspiration. We're excited to continue pushing our product portfolio boundaries to more effectively meet the needs of both patients and providers.”
The umbilical cord (UC) is an essential part of the placenta, forming within the first weeks of gestation by the enclosure of blood vessels into a bulk of mucous connective tissue, named Wharton's jelly, and lined by the umbilical epithelium. The cells populating each component of the cord--Wharton's jelly, the lining epithelium, the sub-amnion layer, the perivascular region, and the blood vessels--are a reservoir of progenitor populations which are collectively grouped as mesenchymal stem cells (MSCs), which can differentiate towards mature cell types belonging to all the three germ layers.
Related Links:
StimLabs
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Tourniquet System
heidi– mein Tourniquet
New
Wound Irrigation Solution
Prontosan®
Latest Critical Care News
- Noninvasive Monitoring Device Enables Earlier Intervention in Heart Failure
- Automated IV Labeling Solution Improves Infusion Safety and Efficiency
- First-Of-Its-Kind AI Tool Detects Pulmonary Hypertension from Standard ECGs
- 4D Digital Twin Heart Model Improves CRT Outcomes
- AI Turns Glucose Data Into Actionable Insights for Diabetes Care
- Microscale Wireless Implant Tracks Brain Activity Over Time
- Smart Mask Delivers Continuous, Battery-Free Breath Monitoring
- Routine Blood Pressure Readings May Identify Risk of Future Cognitive Decline
- CGM-Based Algorithm Enhances Insulin Dose Adjustment in Type 2 Diabetes
- Fish Scale–Based Implants Offer New Approach to Corneal Repair
- Dual-Function Wound Patch Combines Infection Sensing and Treatment
- Smartwatch Signals and Blood Tests Team Up for Early Warning on Insulin Resistance
- Smart Fabric Technology Aims to Prevent Pressure Injuries in Hospital Care
- Standardized Treatment Algorithm Improves Blood Pressure Control
- Combined Infection Control Strategy Limits Drug-Resistant Outbreak in NICU
- AI Helps Predict Which Heart-Failure Patients Will Worsen Within a Year
Channels
Artificial Intelligence
view channel
AI Analysis of Pericardial Fat Refines Long-Term Heart Disease Risk
Accurately identifying long-term cardiovascular disease risk in asymptomatic adults remains challenging for clinicians. Missed or underestimated risk delays preventive therapy and increases the chance... Read more
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read more
Surgical Techniques
view channel
Ultrasound Technology Aims to Replace Invasive BPH Procedures
Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary tract symptoms in aging men and often requires invasive procedures or prolonged recovery. With prevalence expected to rise as populations... Read more
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read more
Patient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Health IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Business
view channel
GE HealthCare Leads Major European Initiative to Advance Cardio-Oncology Care
Cardiovascular complications are increasingly recognized among people undergoing or recovering from cancer treatment, driven by pre‑existing disease and the cardiotoxic effects of chemotherapy, radiotherapy,... Read more
